雷诺瓦罗通过股票交易收购预测瘤学,以推进人工智能驱动的癌症治疗. Renovaro acquires Predictive Oncology in a stock deal to advance AI-driven cancer treatments.

由AI驱动的一家药物发现公司 -- -- 预测肿瘤学公司 -- -- 定由Renovaro通过股票交易所收购,目的是通过AI综合平台加强癌症治疗。 Predictive Oncology, an AI-driven drug discovery firm, is set to be acquired by Renovaro through a stock exchange, aiming to enhance cancer treatment through integrated AI platforms. 这次合并须经股东批准和1 500万美元筹资,有望节省大量费用,并旨在通过将Renovaro的人工智能能力与预测肿瘤学的广泛肿瘤样本生物库相结合,改善患者的结果。 The merger, subject to shareholder approval and $15M fundraising, promises significant cost savings and aims to improve patient outcomes by combining Renovaro's AI capabilities with Predictive Oncology's extensive biobank of tumor samples. 这项交易可以导致早期诊断、个性化治疗和更好地监测癌症患者的复发情况。 The deal could lead to early diagnosis, personalized treatments, and better recurrence monitoring for cancer patients.